2008 French National Guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 1, 2010, Pages 31-46

  Farge, Dominique ^a   Bosquet, Lise ^b   Kassab Chahmi, Diana ^b   Mismetti, Patrick ^c   Elalamy, Ismail ^d   Meyer, Guy ^e   Cajfinger, Francis ^f   Desmurs Clavel, Hélène ^g   Elias, Antoine ^h   Grange, Claire ⁱ   Hocini, Hamid ^a   Legal, Grégoire ^j   Mahe, Isabelle ^k   Quéré, Isabelle ^l   Levesque, Hervé ^m   Debourdeau, Philippe ⁿ  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT NATIONAL DU CANCER   (France)

^c HÔPITAL NORD   (France)

^d HÔPITAL TENON   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h Hopital Font Pre   (France)

ⁱ CENTRE HOSPITALIER LYON SUD   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k HÔPITAL LOUIS MOURIER   (France)

^l HÔPITAL SAINT ELOI   (France)

^m Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

ⁿ Servicc lie Pneumologie Hôpital d'lnstruction des Armées Desgenettes   (France)

more..

Author keywords

Cancer; Clinical practice guidelines; Low molecular weight heparins; Thrombolytics; Unfractionated heparin; Vena cava filters; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER PATIENT; CANCER STAGING; COMPRESSION GARMENT; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBRINOLYTIC THERAPY; FRANCE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; METASTASIS; MORTALITY; PRACTICE GUIDELINE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SOLID TUMOR; THROMBOCYTOPENIA; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

EID: 77953580551     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.004     Document Type: Review

References (69)

1. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164: 963-8.
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton 3rd LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-15.
3. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-64.
4. Sauve C, Boffa MC, Meyer G, Farge-Bancel D. Maladie thromboembolique veineuse et cancer. Rev Med Intern 2000;21:266-77.
5. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782-7.
6. Alcalay A, Wun T, KhatriV, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006;24:1112-8.
7. Khorana AA, FrancisCW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-90.
8. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-68.
9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
10. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl.):401S-28S.
11. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 2006;59:194-204.
12. Fervers B, Hardy J, Blanc-VincentMP, et al. SOR: project methodology. Br J Cancer 2001;84(Suppl. 2):8-16.
13. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23.
14. French national cancer institute. Available at: http://www.e-cancer.fr/.
15. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005;3:692-4.
16. Cucherat M. Guide de lecture critique d'un essai thérapeutique. Médecine Thérapeutique 2006;12:354-8.Available at: http://www.spc.univ-lyon1.fr/lecture-critique/grille%20de%20lecture/frame1.htm/.
17. Calligaro KD, Bergen WS, Haut MJ, Savarese RP, DeLaurentis DA. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Ann Vasc Surg 1991;5:186-9.
18. Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med 1992;22:119-22.
19. Debourdeau P, Meyer G, Sayeg H, et al. Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. A propos d'une série rétrospective de 71 patients. Rev Med Intern 1996;17:207-12.
20. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72.
21. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A metaanalysis. Arch Intern Med 1995;155:601-7.
22. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecularweight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269-77.
23. Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR. Low molecular weight heparin versus unfractionated heparin in the initial treat ment of venous thromboembolism. Curr Opin Pulm Med 1998;4: 220-5.
24. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
25. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160: 181-8.
26. Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000;85:935-42.
27. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004;140:175-83.
28. Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005;128:2203-10.
29. Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 2000;23:71-3.
30. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-10.
31. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
32. Vucic N, Ostojic R, Svircic T. Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study. Croat Med J 2002;43:296-300.
33. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecularweight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35.
34. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
35. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed bywarfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-96.
36. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006;130:1808-16.
37. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: metaanalysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:1906-13.
38. Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005;19:197-201.
39. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ 2006;332:577-80.
40. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Attenuation over 24 h of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J 1997;134:603-7.
41. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991;109:12-5.
42. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer 1992;70:1993-6.
43. Hubbard KP, Roehm Jr JO, Abbruzzese JL. The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies. Am J Clin Oncol 1994;17:115-7.
44. Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 1996;14:652-7.
45. Greenfield LJ, Proctor MC, Saluja A. Clinical results of Greenfield filter use in patients with cancer. Cardiovasc Surg 1997;5: 145-9.
46. Ihnat DM, Mills JL, Hughes JD, Gentile AT, Berman SS, Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 1998;28:800-7.
47. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002;36:704-7.
48. Wallace MJ, Jean JL, Gupta S, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer 2004;101: 1902-7.
49. Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics 2005;60:361-6.
50. Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovasc Surg 2006;40:287-94.
51. Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 2002;249:1409-12.
52. Altschuler E, Moosa H, Selker RG, Vertosick Jr FT. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990;27:74-6.
53. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993;43:1111-4.
54. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994;73:493-8.
55. NCCN (national comprehensive cancer network). Venous thromboembolic disease. NCCN Clinical Practice Guidelines in Oncology, ed.; 2006. Available at: http://www.nccn.org.
56. Scully MF, Geerts WH, Kovacs M, Lee A. Clinical guide - cancer & thrombosis. The Thrombosis Interest Group of Canada, ed. 08/5 A.D. Available: http://www.tigc.org.
57. Lyman GH, Khorana AA, FalangaA, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatments in patients with cancer. J Clin Oncol 2007;25:5490-505.
58. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-52.
59. Dranitsaris G, Vincent M, Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics 2006;24:593-607.
60. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15.
61. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983;13:334-6.
62. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993;70:393-6.
63. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, Al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991;68: 2621-4.
64. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994;69:329-32.
65. Valladares JB, Hankinson J. Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery 1980;6:138-41.
66. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001;7:326-31.
67. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008;133(6 Suppl.):454S-545S.
68. Akl EA, Rohilla S, Barba M, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008;(1):CD006649.
69. Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008;(2):CD006650.